MIRAL SADARIA GRANDHI, MD

Plain English
This study looked at how different levels of liver therapies aimed at curing colorectal cancer that has spread to the liver affected patients' survival rates. Researchers analyzed data from nearly 35,000 patients and found that increasing the rate of these therapies by just 5% led to a 1.2% increase in survival rates. This is important because it shows that getting more patients access to these curative treatments can significantly improve their chances of living longer. Who this helps: This helps patients with colorectal cancer liver metastases.

Plain English
This study looked at how many liver surgeons are available to treat older patients with colorectal cancer that has spread to the liver. Researchers found that there were only 421 surgeons for about 16,700 patients, meaning many people (42.4%) lived where there were no liver surgery options. Those living near a liver surgeon had a better chance of receiving an evaluation and a reduced risk of death, showing that access to surgeons directly affects patient survival. Who this helps: This helps patients with colorectal cancer liver metastases by improving their chances of getting necessary treatments.

Plain English
This study looked at surgeries to remove part of the pancreas in patients with a condition called intraductal papillary mucinous neoplasm (IPMN), focusing on changes from 2014 to 2019. Out of 3,912 patients, 21% had cancer while 79% did not. Overall, the rate of surgeries remained stable, but more patients are now having robotic surgery, which increased from 9.1% to 16.5%, and the rate of a serious complication called clinically relevant postoperative pancreatic fistula dropped from 18.8% to 13.8%. Who this helps: This research benefits patients with IPMN and their doctors by highlighting improvements in surgical methods and outcomes.

Plain English
This study looked at how adjuvant chemotherapy affects patients with Stage II-IV colorectal cancer after they have had surgery to remove tumors. Researchers found that patients who received chemotherapy had significantly lower rates of cancer returning within the first year compared to those who only had surgery: 9% experienced a return of cancer within the first six months, compared to 22% in the surgery-only group. Chemo helped more in the short term, but the differences in outcomes became smaller after the first year. Who this helps: This research benefits colorectal cancer patients by highlighting the importance of chemotherapy in preventing early recurrence.

Plain English
This study looked at how race and ethnicity affect the likelihood of finding invasive tumors in patients undergoing surgery for a precancerous condition of the pancreas called intraductal papillary mucinous neoplasms. Out of 4,505 cases examined, 20.5% had invasive cancer, with Black patients at 24.2%, Asian patients at 23.7%, and Hispanic patients at 22.6%, compared to 19.9% for non-Hispanic White patients. This difference in invasive cases can't be explained by overall health or age factors, which means that non-White patients face higher risks, and recognizing this can help doctors improve early interventions and treatment strategies. Who this helps: This helps patients from diverse racial and ethnic backgrounds facing pancreatic cancer risks.

Plain English
This study looked at two types of appendiceal cancer—mucinous and non-mucinous—and how much of the tumor needs to be surgically removed to improve survival. Out of nearly 4,700 patients, 68% had their entire colon removed, and while this helped patients with non-mucinous cancer (especially those with medium to high tumor grades), it didn't improve survival for those with mucinous cancer at all. This finding suggests that patients with mucinous appendiceal adenocarcinoma might not need such extensive surgery, which could reduce unnecessary procedures and their associated risks. Who this helps: This helps patients with mucinous appendiceal cancer by potentially sparing them from more invasive surgery.

Plain English
This study examined how neighborhood wealth affects young adults (under 50) with colorectal cancer. It found that those living in poorer neighborhoods were 13% more likely to have advanced cancer when diagnosed and had a 45% higher risk of dying compared to those from wealthier areas. Additionally, non-Hispanic Black patients faced more severe outcomes, including being less likely to have surgery and having lower survival rates. Who this helps: This research benefits patients, particularly young adults with colorectal cancer and those from low-income or minority communities.

Plain English
Researchers tracked cancer surgeries for the pancreas and liver during COVID-19 to see if the pandemic disrupted treatment. They found that pancreatic cancer surgeries continued at normal rates throughout the pandemic, while liver cancer surgeries dropped briefly at the start but quickly returned to normal levels—and more pancreatic cancer patients received chemotherapy before surgery during the pandemic. This matters because it shows hospitals prioritized cancer operations during COVID-19, meaning patients with these deadly cancers didn't face major treatment delays, though the increased use of pre-surgery chemotherapy suggests doctors may have changed their approach to managing these patients.

Plain English
This research looked at how combining immunotherapy and radiation therapy can improve treatment for gastrointestinal cancers. The findings from various studies, including some larger studies, show that adding immunotherapy to standard treatments can lead to better survival rates, although the exact timing and ways to combine these treatments are still being worked out. This matters because it opens up new possibilities for more effective cancer treatments, potentially leading to longer lives for patients. Who this helps: This helps patients with gastrointestinal cancers.

Plain English
This study looked at how patients with intrahepatic cholangiocarcinoma (ICC), liver metastases from colorectal cancer (CRLM), and hepatocellular carcinoma (HCC) fared after liver surgery called hepatectomy. It found that 4.8% of ICC patients died within 30 days of surgery, compared to 2.5% for HCC and just 1.0% for CRLM. Additionally, ICC patients faced more complications and a higher likelihood of needing to return to the hospital after surgery. Who this helps: This information helps doctors better prepare and inform their patients about the risks associated with liver surgery for ICC.

Plain English
This study looked at the use of robotic surgery for a complex procedure called pancreatoduodenectomy (PD) over six years. It found that robotic surgeries increased from 2.8% to 7.5% of all PD cases, with fewer complications and shorter hospital stays compared to traditional methods—9.5 days in the hospital for robotic surgery versus 10.9 days for other types. However, medical trainees aren't getting enough practice, as there are only about 5 robotic cases per trainee each year, which is not enough to become proficient. Who this helps: This benefits patients undergoing PD by providing safer and more efficient surgical options.

Plain English
This study looked at older patients undergoing surgery for stomach and intestinal cancers to understand the impact of age on complications after surgery, known as "failure-to-rescue" (FTR). Researchers found that the older patients were, the more likely they were to experience FTR: those aged 56-65 were 87% more likely, 66-75 were over 3 times more likely, and those 76 and older were nearly 6 times more likely to face FTR compared to younger patients. This finding is important because it highlights that simply being older is a strong indicator of risks after surgery, which should be carefully considered when deciding if a patient is fit for surgery. Who this helps: This helps doctors determine surgical risks for older patients with cancer.

Plain English
This research looked at the link between specific genetic changes (mutations) and how they affect the behavior of pancreatic cancer cells in tumors from 321 patients. The study found that 26.8% of the patients had these mutations, and while some were linked to poorer survival rates, especially in specific conditions, the mutations themselves did not affect the cancer's characteristics or patient outcomes. This means more targeted clinical trials are needed to improve treatment for pancreatic cancer. Who this helps: This helps patients with pancreatic cancer and their doctors by identifying the need for better treatment options.

Plain English
This study looked at a rare case of a 45-year-old woman who had liver masses that appeared cancerous but were actually caused by a parasitic infection transmitted through contaminated soil. After treatment with ivermectin for two weeks, her liver issues completely resolved. This is important because it shows that doctors should consider parasitic infections when diagnosing liver problems, as early treatment can lead to better outcomes and avoid unnecessary surgeries. Who this helps: This helps patients with unexplained liver issues and doctors diagnosing similar cases.

Plain English
This study looked at a complex type of surgery for patients with pancreatic cancer called radical antegrade modular pancreatosplenectomy (RAMPS), particularly when the cancer has spread to the adrenal gland. Researchers found that patients undergoing RAMPS experienced more complications and longer hospital stays compared to those having a standard surgery, with issues like needing more blood transfusions and a 36% higher chance of serious problems after surgery. This information is important because while RAMPS may be better for cancer control, it also comes with greater risks that doctors must consider when deciding on treatment options. Who this helps: Patients with pancreatic ductal adenocarcinoma and their doctors.

Plain English
Researchers examined how COVID-19 affected surgery rates for gut cancers across the United States from 2019 to 2022, analyzing nearly 96,000 operations on the esophagus, stomach, colon, and rectum. They found that surgery for esophageal and rectal cancers dropped significantly and stayed low throughout the pandemic, while stomach and colon cancer surgeries initially fell but bounced back to normal levels within a few months. This matters because delays in cancer surgery can allow tumors to grow and spread, potentially worsening patient outcomes and survival rates.

Plain English
This study looked at a rare case of a unique pattern in the blood supply to the liver, specifically a conjoined right hepatic artery made up of branches from other arteries. They observed this in a 54-year-old woman with liver cancer who was preparing for a specific treatment. Finding these unusual anatomical variations matters because they can significantly impact how doctors plan surgical procedures and treatments, ensuring better outcomes for patients. Who this helps: This helps patients undergoing liver cancer treatments and their doctors.

Plain English
This research paper examines a rare and aggressive type of kidney tumor called epithelioid angiomyolipoma (EAML), particularly in a patient whose tumor measured 36 centimeters and spread to the lungs. The case highlights how the patient underwent surgery to remove the tumor and was treated with a medication that targets specific cell pathways, showing a possible way to manage such severe cases. Understanding EAML and its treatment is crucial because it can help improve outcomes for patients with this aggressive type of cancer. Who this helps: Patients with aggressive kidney tumors and their doctors.

Plain English
This study looked at how often patients with pancreatic cancer received chemotherapy before surgery over five years and how this affected their recovery. Researchers found that the use of this treatment (called neoadjuvant therapy) rose from 24.2% in 2014 to 42.7% in 2019, and patients who received it had fewer serious complications and were more likely to have successful surgeries. Specifically, those who got neoadjuvant therapy had a 43% higher chance of optimal surgical results and lower rates of issues like infections and reoperations. Who this helps: This helps patients with pancreatic cancer by potentially improving their surgery outcomes and recovery.

Plain English
This study examined how surgery impacts survival for patients with advanced gastric cancer that has spread to other parts of the body. Researchers analyzed data from nearly 19,000 patients and found that those who had surgery on the primary tumor or distant sites lived longer, with a median survival of about 15.8 to 15.9 months, compared to just 8.6 months for patients who did not have surgery. This is important because it shows that surgery can significantly improve survival, encouraging more exploration of surgical options for these patients. Who this helps: This helps patients with metastatic gastric cancer and their healthcare providers.

Plain English
This study looked at over 108,000 patients who had kidney surgery to see how having a blood clot (venous thromboembolism or VTE) before surgery affected their outcomes. Researchers found that 1.2% of these patients had VTE, and those patients faced higher risks: they were 2.5 times more likely to have major complications and twice as likely to die within 90 days after surgery compared to those without VTE. This matters because it highlights the need for careful evaluation and management of patients with VTE before kidney surgery to improve their chances of recovery and reduce healthcare costs. Who this helps: This helps doctors and patients with kidney conditions considering surgery.

Plain English
This study looked at how metabolic syndrome (which includes obesity, diabetes, and high blood pressure) affects patients undergoing a specific type of surgery called pancreatoduodenectomy (PD). It found that 7.3% of the 19,054 patients studied had metabolic syndrome, and those patients faced higher risks: for example, 30-day mortality was 3% for those with metabolic syndrome compared to 1.8% for those without, and serious complications occurred in 26% of patients with metabolic syndrome versus 23% in others. This is important because it highlights the need for special care strategies to help reduce risks for these patients during and after surgery. Who this helps: This helps patients with metabolic syndrome who are undergoing surgery, as well as the doctors treating them.

Plain English
Researchers looked at the effects of neoadjuvant therapy (NAT) on patients with early-stage pancreatic cancer who underwent surgery. They found that using NAT reduced the rates of positive margins—where cancer cells are found at the edges of the removed tissue—from 21.8% to 15.5%. When radiation therapy was also used, those rates dropped even further to 13.4%. This is important because having fewer positive margins is linked to better survival rates, with patients having positive margins living an average of 14.9 months compared to 23.9 months for those without. Who this helps: This helps patients with early-stage pancreatic cancer and their doctors in making informed treatment decisions.

Plain English
This study looked at how two different chemotherapy drugs, capecitabine (CAPE) and gemcitabine (GEM), performed in combination with radiation therapy before surgery in patients with borderline resectable and resectable pancreatic cancer. It found that patients taking CAPE had a much better chance of having their tumors surgically removed (almost 10 times more likely) and lived longer without their cancer worsening (15.4 months compared to 4.0 months for GEM). Thus, using CAPE may improve treatment outcomes for these patients. Who this helps: This research benefits pancreatic cancer patients who are considering surgery.

Plain English
This research looked at a rare change in blood vessel anatomy where the right and common hepatic arteries were replaced by a single vessel called the lienogastric trunk in a patient with liver cancer. This unusual arrangement could affect how doctors plan surgeries or treatments for similar patients. Understanding such variations is important to avoid complications and improve patient care. Who this helps: This helps doctors treating patients with liver cancer or related conditions.

Plain English
This research looked at different subcategories of T1 stage pancreatic cancer to see how they affect survival rates in patients who had surgery. They analyzed data from over 41,000 patients and found that the 5-year survival rates for T1a (68.8%), T1b (57%), and T1c (46.6%) patients showed differences, indicating that smaller tumors generally lead to better outcomes. However, when looking at a more in-depth analysis, the distinction between the categories was not significant across all cases. Who this helps: This benefits patients with pancreatic cancer and their doctors by providing clearer survival expectations based on tumor size.

Plain English
The study focused on improving treatments for patients with unresectable hepatocellular carcinoma (HCC), a serious liver cancer that many patients cannot be cured from due to its advanced state. Researchers found that combining external beam radiation therapy (EBRT) with other treatments like transarterial chemoembolization (TACE) can lead to better outcomes for these patients, particularly those with three or fewer large tumors or other complications. This matters because with effective treatment options, patients may have a better quality of life and extended survival times. Who this helps: Patients with advanced liver cancer who cannot undergo surgery.

Plain English
This study looked at treatments to improve survival for patients with resectable pancreatic adenocarcinoma, a type of pancreatic cancer that can be surgically removed. Researchers found that using a combination of gemcitabine and capecitabine or a specific chemotherapy regimen called modified FOLFIRINOX improved survival rates compared to using gemcitabine alone. Many patients still face a poor prognosis even after surgery, so finding effective post-surgery treatments is crucial. Who this helps: This benefits patients with resectable pancreatic cancer.

Plain English
This research paper focuses on the importance of surgical margins when removing liver tumors, specifically hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The study found that for HCC, patients who had their tumors removed with wider margins had better outcomes compared to those with narrower margins. Similarly, patients with ICC experienced worse outcomes if their surgery left microscopic cancer cells behind (known as R1 resection). This is important because having wider margins can improve survival rates and lower the chances of the cancer returning. Who this helps: This helps patients with liver tumors and their doctors.

Plain English
This study examines hepatocellular carcinoma (HCC), the most common type of primary liver cancer, which makes up about 90% of liver cancer cases and is a leading cause of cancer deaths worldwide. The research highlights that surgery and liver transplants are the best options for early-stage HCC, while other treatments like targeted therapy are important for more advanced cases. This matters because a team of specialists must work together to choose the right treatment plan to improve survival rates and patient outcomes. Who this helps: This helps patients with liver cancer and their healthcare teams.

Plain English
This study focused on patients with neuroendocrine tumors that have spread, particularly to the liver. Researchers found that over half of these patients have liver metastases at diagnosis, and combining local treatments like surgery and liver-specific therapy with systemic therapies (like targeted drugs) significantly improves patient outcomes. This matters because it shows that a comprehensive treatment plan is crucial for managing this complex cancer effectively. Who this helps: Patients with metastatic neuroendocrine tumors and their doctors.

Plain English
This study looked at how a special process called ex vivo lung perfusion (EVLP) can help evaluate and successfully transplant lungs from people who died by hanging. Researchers tested lungs from five such donors, and they found that three out of those five met the necessary health criteria for transplantation after being treated with EVLP. This is important because it shows that using EVLP can expand the pool of available donor lungs, potentially saving more lives through transplantation. Who this helps: This helps patients in need of lung transplants.